Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

LLY Eli Lilly and Company Today Eli Lilly and Company $904.76 -0.62 (-0.07%) 52-Week Range $434.34 $915.79 Dividend Yield 0.57% P/E Ratio 133.25 Price Target $812.72 Add to Watchlist Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss. Zepbound is prescribed for obesity treatment. The active ingredient in both is Tirzepatide. Lilly submi ...